{Reference Type}: Journal Article
{Title}: Versatile Design of NO-Generating Proteolipid Nanovesicles for Alleviating Vascular Injury.
{Author}: Yang Y;Zhang X;Yan H;Zhao R;Zhang R;Zhu L;Zhang J;Midgley AC;Wan Y;Wang S;Qian M;Zhao Q;Ai D;Wang T;Kong D;Huang X;Wang K;
{Journal}: Adv Sci (Weinh)
{Volume}: 11
{Issue}: 31
{Year}: 2024 Aug 17
{Factor}: 17.521
{DOI}: 10.1002/advs.202401844
{Abstract}: Vascular injury is central to the pathogenesis and progression of cardiovascular diseases, however, fostering alternative strategies to alleviate vascular injury remains a persisting challenge. Given the central role of cell-derived nitric oxide (NO) in modulating the endogenous repair of vascular injury, NO-generating proteolipid nanovesicles (PLV-NO) are designed that recapitulate the cell-mimicking functions for vascular repair and replacement. Specifically, the proteolipid nanovesicles (PLV) are versatilely fabricated using membrane proteins derived from different types of cells, followed by the incorporation of NO-generating nanozymes capable of catalyzing endogenous donors to produce NO. Taking two vascular injury models, two types of PLV-NO are tailored to meet the individual requirements of targeted diseases using platelet membrane proteins and endothelial membrane proteins, respectively. The platelet-based PLV-NO (pPLV-NO) demonstrates its efficacy in targeted repair of a vascular endothelium injury model through systemic delivery. On the other hand, the endothelial cell (EC)-based PLV-NO (ePLV-NO) exhibits suppression of thrombosis when modified onto a locally transplanted small-diameter vascular graft (SDVG). The versatile design of PLV-NO may enable a promising therapeutic option for various vascular injury-evoked cardiovascular diseases.